China
Africa
Explore chapters and articles related to this topic
Rheumatoid Arthritic Pain
Published in Andrea Kohn Maikovich-Fong, Handbook of Psychosocial Interventions for Chronic Pain, 2019
Natasha S. DePesa, Chelsea Wiener, Jeffrey E. Cassisi
Unlike the more common osteoarthritis (OA), which involves mechanical “wear and tear” of joint cartilage, RA is an autoimmune disorder. During the course of RA, immune cells attack the synovial membranes, or the flexible capsules surrounding joints, resulting in chronic inflammation, pain, stiffness, and eventual damage to cartilage and bone (Aletaha et al., 2010). Clinical synovitis (“swelling”) of joints is necessary for diagnosis, with greater small joint involvement being characteristic of RA. Diagnosis can be made by clinical examination, and determination that swelling is not better accounted for by another etiology. Diagnosis also is aided by anti-citrullinated protein antibody (ACPA) and rheumatoid factor (RF) serology tests and other blood tests of acute phase reactants such as C-reactive protein and erythrocyte sedimentation rate (Aletaha et al., 2010).
Favorable clinical response and drug retention of anti-IL-6 receptor inhibitor in rheumatoid arthritis with high CRP levels: the ANSWER cohort study
Published in Scandinavian Journal of Rheumatology, 2022
Y Nakayama, M Hashimoto, R Watanabe, K Murakami, K Murata, M Tanaka, H Ito, W Yamamoto, K Ebina, K Hata, Y Hiramatsu, M Katayama, Y Son, H Amuro, K Akashi, A Onishi, R Hara, K Yamamoto, K Ohmura, S Matsuda, A Morinobu
However, although the clinical remission rates are similar between bDMARDs with varied mechanisms of action, each bDMARD displays a differential clinical efficacy under a specific clinical situation. Thus, although the overall efficacy with TNFi (ADA) and CTLA4-Ig (ABT) was the same, CTLA4-Ig showed an improved clinical response in patients with high titres of anti-citrullinated protein antibody (ACPA) in the AMPLE study (4). In RA patients with anaemia, IL-6Ri treatment gave a favourable clinical response that resulted in remission, whereas TNFi treatment saw a progression in structural damage (5–7). TNFi, but not CTLA4-Ig or IL-6Ri, showed reduced response rates in RA patients with high titres of rheumatoid factor (RF) (8, 9). These studies highlight the need to determine which bDMARDs show a better clinical response in specific clinical situations in a real-world setting.
Value of serum collagen triple helix repeat containing-1(CTHRC1) and 14-3-3η protein compared to anti-CCP antibodies and anti-MCV antibodies in the diagnosis of rheumatoid arthritis
Published in British Journal of Biomedical Science, 2021
T Hu, Y Liu, L Tan, J Huang, J Yu, Y Wu, Z Pei, X Zhang, J Li, L Song, W Dai, Y Xiang
Collagen triple helix repeat containing-1 (CTHRC1) promotes bone and cartilage erosion and pannus formation by activating fibroblast-like synoviocytes (FLS) and so may be a marker for the diagnosis of RA [2]. 14-3-3η protein is significantly increased in serum and joint synovial fluid of RA patients and can up-regulate the expression of a variety of RA-related inflammatory factors [3,4], suggesting that it may be involved in pathogenesis. Anti-citrullinated protein antibody (ACPA) testing is a significant breakthrough in RA laboratory diagnosis. Anti-cyclic citrullinated peptide antibodies (anti-CCP) and anti-mutated citrullinated vimentin antibodies (anti-MCV) have high specificity for the diagnosis of RA [5,6]. Rheumatoid factor is the first serological indicator for the diagnosis of RA. Erythrocyte sedimentation rate (ESR) is a simple and reproducible acute phase response indicator. Despite this, these indices are rarely compared in a disease-controlled study. We therefore set out to determine which indices can be used alone or in combination to provide the highest diagnostic value for RA. We selected 103 RA patients, 105 non-RA patients with inflammatory joint disease and 59 healthy controls in the Second Affiliated Hospital of Nanchang University from December 2018 to December 2019, and serum CTHRC1, 14-3-3η protein, ACPA, RF and ESR levels were detected. The analysis results were reported as follows.
IRAK1 Gene Polymorphism in Rheumatoid Arthritis
Published in Immunological Investigations, 2021
Najme Hosseini, Mohammad Taher Tahoori, Adel Mohammadzadeh, Hossein Zarei Jaliani, Morteza Bitaraf Sani, Hosein Soleimani Salehabadi
Rheumatoid arthritis (RA) is known as a long-lasting inflammatory autoimmune disease affecting the diarthrodial joints, which is diagnosed by inflammation and hyperplasia in synovium, generation of RF and anti–citrullinated protein antibody (ACPA), deformity of cartilage and bone, systemic injuries involving cardiovascular, pulmonary, psychological, and skeletal disorders (McInnes and Schett 2011). The course of RA varies from mild swelling of joint to severe polyarthritis associated with the destruction of cartilage and bones (Dörr et al. 2004). The incidence of RA is relatively constant in different populations with a prevalence rate of 0.5–1.0% (Silman and Pearson 2002). RA can occur at any age but it is more common among 35–50 year-old individuals, and has three times higher incidence in women than in men (Chung et al. 2016). Although the cause of rheumatoid arthritis is unknown, a number of immunological, genetic, environmental, infectious, and hormonal factors have been implicated in RA pathogenesis (Bowes and Barton 2008).